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We report the ﬁrst case of a heterozygous T78M mutation in the caveolin-3 gene (CAV3) associated with rippling muscle disease and
proximal myopathy. The patient displayed also bilateral winged scapula with limited abduction of upper arms and marked asymmetric
atrophy of leg muscles shown by magnetic resonance imaging. Immunohistochemistry on the patient’s muscle biopsy demonstrated a
reduction of caveolin-3 staining, compatible with the diagnosis of caveolinopathy. Interestingly, consistent with the possible diagnosis
of FSHD, the patient carried a 35 kb D4Z4 allele on chromosome 4q35. We discuss the hypothesis that the two genetic mutations
may exert a synergistic eﬀect in determining the phenotype observed in this patient.
 2011 Elsevier B.V.
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Caveolinopathies, clinically heterogeneous neuromuscu-
lar and/or cardiac diseases, mainly present as limb girdle
muscular dystrophy type 1C (LGMD-1C) or inherited rip-
pling muscle disease (RMD), characterized by electrically
silent percussion-induced muscle mounding. However,
these disorders also include isolated hyperCKemia, distal
myopathy (MD) [1,2], familial hypertrophic cardiomyopa-
thy (HCM) [3], arrhythmogenic long QT syndrome (LQTS)
[4] and some cases of sudden infant death syndrome (SIDS)0960-8966 2011 Elsevier B.V.
doi:10.1016/j.nmd.2011.12.001
⇑ Corresponding author.
E-mail address: g_ricci@alice.it (G. Ricci).
Open access under CC BY-NC-ND license.[5]. All these disorders are usually transmitted as an auto-
somal dominant trait and are caused by mutations in the
CAV3 gene (OMIM 601253, gene map locus 3p25), which
encodes for caveolin-3 (Cav-3), the myocyte-speciﬁc iso-
form of caveolin proteins. Caveolins are the main protein
components of caveolae, vesicular invaginations of the
plasma membrane involved in several biological processes
such as cellular vesicular traﬃcking, endocytosis, choles-
terol homeostasis, and signal transduction [6,7]. Functional
studies of diﬀerent CAV3 missense mutations have shown
that mutant Cav-3 can be held in the Golgi apparatus
and rapidly degraded by the ubiquitin–proteasome system,
exerting a dominant negative eﬀect on the wild-type protein
[8–10], thereby explaining the dominance of these
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ferent phenotypes, sometime overlapping, in diﬀerent indi-
viduals, suggesting that additional unknown loci aﬀect the
disease phenotypes. However, muscle impairment and car-
diac dysfunction rarely coexist in a patient, probably due to
the involvement of distinct pathogenic molecular pathways
[11,12].
Facioscapulohumeral muscular dystrophy (FSHD) is an
autosomal dominant neuromuscular disorder, character-
ized by progressive weakness of the facial, shoulder girdle
and upper limb muscles, often involving peroneal and pel-
vic girdle muscles. The molecular bases of this disease are
unknown, but the disorder is associated with DNA rear-
rangements of a polymorphic array of tandemly repeated
3.3 kb DNA segments (named D4Z4 repeats) located at
the subtelomeric region of chromosome 4q [13]. It has been
established that normal subjects carry p13E-11 EcoRI
digested alleles larger than 50 kb (P11 D4Z4 repeats)
originating from chromosome 4, while the majority of
either de novo or familial FSHD patients carries alleles of
35 kb, corresponding to 8 D4Z4 units, or shorter [14].
Genotype–phenotype correlation studies have revealed an
inverse correlation between the number of D4Z4 repeats
and the severity of the disease. Nevertheless, the variability
of clinical outcomes has resulted to be more pronounced
than expected [15,16], even within the same family
[17,18]. In addition, subjects carrying reduced D4Z4 allele
without signs of the disease have also described
[15,16,19]. To explain the clinical variability and the pres-
ence of non-penetrant carriers, recent studies have sug-
gested that reduction of D4Z4 repeats on chromosome
4q35 is pathogenic only in certain “permissive” chromo-
somal backgrounds, such as polymorphisms that map at
the distal region of chromosome 4q and chromosome 10q
[20–22].
Here we report on a patient with rippling myopathy,
limb girdle muscle weakness and some phenotypic features
reminiscent of FSHD, who proved to be a carrier of a het-
erozygous CAV3 mutation and a D4Z4 FSHD-sized allele.Fig. 1. Proband with bilateral mild wingeThe observed phenotype was consistent with these combined
genetic mutations in determining an “overlapping” syndrome.
2. Case description
The proband, a 55-year-old Caucasian male, born to
non-consanguineous parents, was delivered at term after
an uneventful pregnancy. He achieved normal developmen-
tal motor milestones. His remote pathological anamnesis
was unremarkable. At the age of 45, the patient began to
complain of limb girdle fatigability and muscle weakness
with diﬃculty in some motor tasks, such as raising the
upper limbs or climbing stairs. Since the age of 53, he
had also been experiencing muscle cramps, pain, stiﬀness
induced by exercise and the occurrence of localized mound-
ing and rapid contractions of lower limb muscles, generally
caused by muscle percussion. Neurological examination
revealed a hyperlordotic posture, bilateral mild winged
scapula (Fig. 1), a partial limitation of arms abduction,
up to 90, and a moderate hyposthenia at the pelvic girdle
muscle level (score 4.5 at MRC grading Hammersmith
Hospital motor scale [23]). Mechanical percussion of thigh
muscle bellies induced a transient local mounding phenom-
enon, resembling RMD [24]. The deep tendon reﬂexes were
mildly reduced. No signs of facial weakness were present.
The family history was inconsistent, although his father
was reported to have diﬃculties in raising arms in his sev-
enties and his mother, who died at age of 70 years from
congestive heart failure, was reported to have heart com-
plaints since age of 35 years, after her last delivery (medical
reports are not available) (Fig. 2).
Blood creatine kinase (CK) level was mildly increased
(up to 1000 U/L; n.v. <190); the routine blood tests and
thyroid hormones were in the normal range. The ischemic
forearm exercise test for lactate dosage showed a delayed
recovery in lactate kinetics after-exercise. Needle electro-
myography revealed myopathic signs in the four limbs;
the involuntary rolling muscle contractions were electri-
cally silent. In order to exclude an immunogenic form ofd scapula and hyperlordotic posture.
Fig. 2. Pedigree of the proband family. Arrow indicates the proband. Proband’s father was reported to have diﬃculties in raising arms in his seventies; he
died at the age of 83 years for Parkinson’s disease. Proband’s mother, aﬀected by congestive heart failure, died at the age of 70 years (medical reports are
not available). The brother, the sister and the two daughters of the proband resulted completely asymptomatic.
Fig. 3. T1-weighted skeletal muscle MRI of the lower limbs: (a) at thigh
level, marked fatty inﬁltration and atrophy of the left long adductor
(arrow); (b) at leg level, fatty inﬁltration of the medial head of the left
gastrocnemius (arrow).
Fig. 4. Quadriceps femoris muscle biopsy: (a) hematoxylin and eosin and (b
connective tissue and diameter variability in both ﬁber types, scattered rou
endomysial inﬂammatory inﬁltrate.
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levels of anti-acetylcholine receptor-antibodies were deter-
mined with a negative result; thoracic computed tomogra-
phy was inconsistent. Cardiac assessment was normal.
Thigh and leg muscle magnetic resonance imaging
(MRI) revealed an asymmetric muscle pattern involve-
ment, with marked fatty inﬁltration and atrophy of long
adductor of the left thigh and medial head of the left gas-
trocnemius (Fig. 3), mild signs of edema in thigh muscles
(right femoral biceps and left gracile muscles) and in leg
muscles (lateral head of the right gastrocnemius and bilat-
eral tibial anterior).
The patient underwent biopsy at the right quadriceps
femoris muscle. The frozen muscle specimen was processed
for routine histology and immunohistochemistry analysis.
Muscle biopsy showed moderate myopathic changes
including increase in connective tissue and diameter vari-
ability in both ﬁber types, scattered round shaped atrophic
ﬁbers, rare degenerative ﬁbers and a considerable endomy-
sial inﬂammatory inﬁltrate (Fig. 4). Immunostaining, per-
formed for dystrophin (dilution 1:20), laminin (dilution
1:50), alfa-sarcoglycan (dilution 1:100), dysferlin (dilution
1:20) and emerin (dilution 1:20) (mouse monoclonal anti-
bodies; Novocastra Ltd., United Kingdom) using a Bench-
mark immunostainer (Ventana Medical System, Tucson,
AZ), was normal.) modiﬁed Gomori’s trichrome staining; magniﬁcation 20. Increase in
nd shaped atrophic ﬁbers, rare degenerative ﬁbers and a considerable
Fig. 5. Skeletal muscle immunostaining for Cav-3 (monoclonal antibodies diluted 1:100 in 1% BSA-PBS; Transduction Laboratories, Lexington, KY) of a
healthy control and of the proband. In the proband the immunolabeling for Cav-3 resulted markedly reduced at the plasmalemma in almost all ﬁbers.
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molecular weight genomic DNA was extracted from
peripheral blood lymphocytes with standard procedures.
Using polymerase chain reaction (PCR), denaturing high-
performance liquid chromatography, and direct DNA
sequencing, the open reading frame/splice site mutational
analysis on CAV3 revealed n.233C > T (T78M) missense
mutation in exon 2, involving a highly conserved residue
in the Cav-3 transmembrane domain [10]. Subsequently
skeletal muscle immunostaining for Cav-3 (monoclonal
antibodies diluted 1:100 in 1% BSA-PBS; Transduction
Laboratories, Lexington, KY) was carried out and resulted
markedly reduced at the sarcolemma in almost all ﬁbers
(Fig. 5), compatible with diagnosis of caveolinopathy [1].
Based on some phenotypic features of the patient,
such as bilateral mild winged scapula and upper limb gir-
dle weakness as well as muscle MRI pattern, facioscapu-
lohumeral muscular dystrophy (FSHD) was also
considered. The molecular test for FSHD, Southern blot
hybridization of EcoRI/BlnI-digested DNA resolved by
pulsed ﬁeld gel electrophoresis detected with probe
p13-E11 [13], revealed an EcoRI restriction fragment of
35 kb on chromosome 4q35. Polymorphisms ﬂanking
the D4Z4 repeat array were also investigated. The
35 kb D4Z4 allele was associated with 4qA variant, 161
Simple Sequence Length Polymorphism (SSLP) and the
permissive Single Nucleotide Polymorphism (SNP)
ATTAAA [20–22].
Molecular analysis for CAV3 gene and FSHD in other
family members (brother, sister and daughters), all com-
pletely asymptomatic, was not performed because they
declined to undergo genetic testing.3. Discussion
We report the ﬁrst case of a heterozygous CAV3 T78M
mutation associated with rippling muscle disease and prox-
imal weakness in which immunohistochemical analysis of
skeletal muscle conﬁrmed reduced Cav-3 immunolabeling.
The heterozygous n.233C > T missense mutation in CAV3
observed in our case is responsible of a threonine to methi-
onine substitution at codon 78 (T78M), a highly conserved
residue of Cav-3. This mutation has originally been
reported in three unrelated individuals with long QT syn-
drome (LQTS) [4]. In particular, one patient, a 14-year-
old girl with non-exertional syncope and a ‘seizure-like’
presentation, carried biallelic digenic mutations, a A913V
mutation in the LQT2-associated KCNH2 gene as well as
the T78M mutation. In contrast, the other two patients
with T78M mutations, an 8-year-old boy with non-exer-
tional syncope and marked sinus bradycardia, and an
asymptomatic 40-year-old male, resulted negative for
mutations in known LQTS genes. A positive family history
was reported in all three patients, but molecular analysis in
other family members was not performed. Subsequently,
Cronk et al. (2007) [5] has identiﬁed the same mutation
in heterozygosis in a 2-month-old black female infant
who died of SIDS. As this patient presented neither pri-
mary cardiomyopathy nor skeletal muscle impairment, it
was speculated that Cav-3 might have a role in cardiac
excitability. Indeed, Cav-3 co-localizes with beta2-adreno-
receptors in ventricular and sinoatrial myocytes, thus sup-
porting the idea that disruption of caveolae can aﬀect the
beta-adrenergic responsiveness and the excitation–contrac-
tion coupling of cardiac myocytes [27–29]. The CAV3
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opathic hyperCKemia, although in this case immunohisto-
chemical analysis of Cav-3 in a muscle biopsy was normal
[30]. More recently, Traverso and coworkers (2008) [10]
have described homozygous T78M mutation in CAV3 in
a 58-year-old woman born to consanguineous parents,
aﬀected by dilated cardiomyopathy and limb girdle muscu-
lar dystrophy. The patient’s daughter, heterozygous for the
mutation, was asymptomatic and had normal CK, suggest-
ing an autosomal recessive mode of inheritance for this
trait. In vitro studies showed that T78M mutated Cav-3
impairs the ability of the Cav-3 hydrophobic domain to
assembly Cav-3 homo-oligomers units for the formation
of caveolae in muscle cells. Thus it was concluded that
the T78M mutation acts through a loss-of-function mech-
anism [31–33]. This hypothesis was consistent with the fact
that the patient carrying a homozygous CAV3 T78M sub-
stitution developed a severe muscular phenotype, whereas
her heterozygous daughter was asymptomatic.
Collectively, published data [4,5,10,30] do not fully sup-
port the hypothesis that CAV3 T78M mutation is patho-
genic in the skeletal muscle in the heterozygous state.
Instead, it can be hypothesized that the CAV3 T78M muta-
tion may exert a pathogenic eﬀect in association with other
genetic factors Indeed, genotype–phenotype correlation
studies suggest that in caveolinopathies genetic modiﬁers
may contribute to determine Cav-3 deﬁciency phenotype
[1,10,12,34].
In our case, the clinical diagnosis of caveolinopathy was
suggested by the presence of rippling phenomenon and
proximal muscle weakness resembling a LGMD phenotype
and was supported by the discovery of CAV3 T78M muta-
tion. The histochemical analysis performed on skeletal
muscle biopsy revealed reduced immunolabeling for Cav-
3, compatible with diagnosis of caveolinopathy [1]. How-
ever, the shoulder girdle involvement presenting with scap-
ular winging observed in our case is unusual in
caveolinopathies, although these disorders are associated
with a broad spectrum of clinical phenotypes [12,35].
Beyond the bilateral winged scapula and the limitation of
upper arms abduction, the patient also displayed other
clinical features reminiscent of FSHD, such as marked
asymmetry at MRI imaging of muscle involvement in the
legs [36,37] and the inﬂammatory inﬁltration observed in
muscle biopsy [38]. Consistent with these clinical observa-
tions we detected a 35 kb D4Z4 allele on chromosome
4q35, which is generally reported in patients with a mild
FSHD phenotype [39]. Further, this was also associated
with the 161A-SNP ATTAAA permissive haplotype [22],
recently proposed as the genetic marker for FSHD [40].
Nevertheless, weakness of the pelvic girdle muscles, as
complained by our patient, is not usually present at onset
in FSHD [41] and the rippling phenomenon, speciﬁc sign
of caveolinopathy, has never been reported associated with
D4Z4 reduced allele.
The extensive use of the molecular analysis as diagnostic
test in human hereditary myopathies has led to theidentiﬁcation of an increasing number of atypical pheno-
types. This is particularly true for FSHD, in which various
clinical features have been found in subjects carrying
FSHD-sized D4Z4 alleles, including a facial-sparing form
of FSHD (SHD) [42], limb-girdle muscular dystrophy
[43], distal myopathy [44], asymmetric brachial weakness
[43], chronic progressive external ophthalmoplegia [45],
asymptomatic hyperCKemia [46], hypertrophic cardiomy-
opathy [47], adult-onset distal myopathies with rimmed
vacuoles [48], isolated axial myopathy with camptocormia
and bent spine syndrome [49,50]. In addition, overlapping
FSHD phenotypes in which 4q35 deleted D4Z4 mutation
is associated with other pathogenic mutations in other
genes, have been reported in cases of patients with mito-
chondrial myopathy/FSHD [51], Becker dystrophy/FSHD
[52], Duchenne dystrophy/FSHD [53,54], Leber’s heredi-
tary optic neuropathy/FSHD [55], suggesting a synergistic
eﬀect of those simultaneous mutations in reaching disease
threshold and determining overlapping phenotypes.
In conclusion, our case may represent a further example
of such atypical phenotypes in which D4Z4 deletion con-
tributes to pathogenicity of heterozygous CAV3 T78M
mutation for the observed myopathic phenotype, resulting
in an overlapping syndrome.
Acknowledgment
Grant support was received from Telethon GUP08004 GS
(RT), AFM 14339 (RT), NIH-NINDS R01 047584 (RT).
References
[1] Fulizio L, Nascimbeni AC, Fanin M, et al.. Molecular and muscle
pathology in a series of caveolinopathy patients. Hum Mutat
2005;25:82–9.
[2] Bruno C, Sotgia F, Gazzerro E, Minetti C, Lisanti MP. Caveolin-
opathies. In: Pagon RA, Bird TD, Dolan CR, Stephens K, editors.
Seattle (WA): University of Washington, Seattle 2007; 1993.
[3] Hayashi T, Arimura T, Ueda K, et al.. Identiﬁcation and functional
analysis of a caveolin-3 mutation associated with familial hypertro-
phic cardiomyopathy. Biochem Biophys Res Commun
2004;313:178–84.
[4] Vatta M, Ackerman MJ, Ye B, et al.. Mutant caveolin-3 induces
persistent late sodium current and is associated with long-QT
syndrome. Circulation 2006;114:2104–12.
[5] Cronk LB, Ye B, Kaku T, et al.. Novel mechanism for sudden infant
death syndrome: persistent late sodium current secondary to muta-
tions in caveolin-3. Heart Rhythm 2007;4(2):161–6.
[6] Monier S, Parton RG, Vogel F, Behlke J, Henske A, Kurzchalia TV.
VIP21-caveolin, a membrane protein constituent of the caveolar coat,
oligomerizes in vivo and in vitro. Mol Biol Cell 1995;6:911–27.
[7] Galbiati F, Razani B, Lisanti MP. Caveole and caveolin-3 in
muscular dystrophy. Trends Mol Med 2001;7:435–41.
[8] Galbiati F, Volonte D, Minetti C, Chu JB, Lisanti MP. Phenotypic
behavior of caveolin-3 mutations that cause autosomal dominant
limb girdle muscular dystrophy (LGMD-1C). Retention of LGMD-
1C caveolin-3 mutants within the golgi complex. J Biol Chem
1999;274:25632–41.
[9] Galbiati F, Volonte D, Minetti C, Bregman DB, Lisanti MP. Limb-
girdle muscular dystrophy (LGMD-1C) mutants of caveolin-3
undergo ubiquitination and proteasomal degradation. Treatment
with proteasomal inhibitors blocks the dominant negative eﬀect of
G. Ricci et al. / Neuromuscular Disorders 22 (2012) 534–540 539LGMD-1C mutanta and rescues wild-type caveolin-3. J Biol Chem
2000;275:37702–11.
[10] Traverso M, Gazzerro E, Assereto S, et al.. Caveolin-3 T78M and
T78K missense mutations lead to diﬀerent phenotypes in vivo and
in vitro. Lab Invest 2008;88(3):275–83.
[11] Catteruccia M, Sanna T, Santorelli FM, et al.. Rippling muscle
disease and cardiomyopathy associated with a mutation in the CAV3
gene. Neuromuscul Disord 2009;19(11):779–83.
[12] Gazzerro E, Sotgia F, Bruno C, Lisanti MP, Minetti C. Caveolin-
opathies: from the biology of caveolin-3 to human diseases. Eur J
Hum Genet 2010;18(2):137–45.
[13] Wijmenga C, Hewitt JE, Sandkuijl LA, et al.. Chromosome 4q DNA
rearrangements associated with facioscapulohumeral muscular dys-
trophy. Nat Genet 1992;2(1):26–30.
[14] Sarfarazi M, Wijmenga C, UpadhyayaM, et al.. Regional mapping of
facioscapulohumeral muscular dystrophy gene on 4q35: combined
analysis of an international consortium. Am J Hum Genet
1992;51(2):396–403.
[15] Ricci E, Galluzzi G, Deidda G, et al.. Progress in the molecular
diagnosis of facioscapulohumeral muscular dystrophy and correlation
between the number of KpnI repeats at the 4q35 locus and clinical
phenotype. Ann Neurol 1999;45(6):751–7.
[16] Tonini MM, Passos-Bueno MR, Cerqueira A, Matioli SR, Pavanello
R, Zatz M. Asymptomatic carriers and gender diﬀerences in
facioscapulohumeral muscular dystrophy (FSHD). Neuromuscul
Disord 2004;14(1):33–8.
[17] Tupler R, Barbierato L, Memmi M, et al.. Identical de novo mutation
at the D4F104S1 locus in monozygotic male twins aﬀected by
facioscapulohumeral muscular dystrophy (FSHD) with diﬀerent
clinical expression. J Med Genet 1998;35(9):778–83.
[18] Fitzsimons RB. Facioscapulohumeral muscular dystrophy. Curr
Opin Neurol 1999;12(5):501–11.
[19] van Overveld PG, Lemmers RJ, Deidda G, et al.. Interchromosomal
repeat array interactions between chromosomes 4 and 10: a model for
subtelomeric plasticity. Hum Mol Genet 2000;9(19):2879–84.
[20] Lemmers RJ, Wohlgemuth M, Frants RR, Padberg GW, Morava E,
van der Maarel SM. Contractions of D4Z4 on 4qB subtelomeres do
not cause facioscapulohumeral muscular dystrophy. Am J Hum
Genet 2004;75(6):1124–30.
[21] Lemmers RJ, Wohlgemuth M, van der Gaag KJ, et al.. Speciﬁc
sequence variations within the 4q35 region are associated with
facioscapulohumeral muscular dystrophy. Am J Hum Genet
2007;81(5):884–94.
[22] Lemmers RJ, van der Vliet PJ, Klooster R, et al.. A unifying genetic
model for facioscapulohumeral muscular dystrophy. Science
2010;329(5999):1650–3.
[23] John J. Grading of muscle power: comparison of MRC and analogue
scales by 279 physiotherapists. Medical research council. Int J
Rehabil Res 1984;7:173–81.
[24] Wiwanitkit V. Bedside diagnosis of rippling muscle disease. Muscle
Nerve 2011;43(1):144.
[25] Schoser B, Jacob S, Hilton-Jones D, et al.. Immune-mediated rippling
muscle disease with myasthenia gravis: a report of seven patients with
long-term follow-up in two. Neuromuscul Disord 2009;19(3):223–8.
[26] Liewluck T. Immune-mediated rippling muscle disease: another
inﬂammatory myopathy in myasthenia gravis. Arch Neurol
2010;67(7):896–7.
[27] Balijepalli RC, Foell JD, Hall DD, Hell JW, Kamp TJ. Localization
of cardiac L-type Ca(2+) channels to a caveolar macromolecular
signaling complex is required for beta(2)-adrenergic regulation. Proc
Natl Acad Sci USA 2006;103:7500–5.
[28] Calaghan S, White E. Caveolae modulate excitation-contraction
coupling and beta2-adrenergic signalling in adult rat ventricular
myocytes. Cardiovasc Res 2006;69:816–24.
[29] Barbuti A, Terragni B, Brioschi C, DiFrancesco D. Localization of f-
channels to caveolae mediates speciﬁc beta2-adrenergic receptor
modulation of rate in sinoatrial myocytes. J Mol Cell Cardiol
2007;42:71–8.[30] Reijneveld JC, Ginjaar IB, Frankhuizen WS, Notermans NC. CAV3
gene mutation analysis in patients with idiopathic hyper-CK-emia.
Muscle Nerve 2006;34(5):656–8.
[31] Parton RG. Caveolae and caveolins. Curr Opin Cell Biol
1996;8:542–8.
[32] Das K, Lewis RY, Scherer PE, et al.. The membrane-spanning
domains of caveolins-1 and -2 mediate the formation of caveolin
heterooligomers. Implications for the assembly of caveolae mem-
branes in vivo. J Biol Chem 1999;274:18721–8.
[33] Schlegel A, Lisanti MP. A molecular dissection of caveolin-1
membrane attachment and oligomerization. Two separate regions
of the caveolin-1 C-terminal domain mediate membrane binding and
oligomer/oligomer interactions in vivo. J Biol Chem
2000;275:21605–17.
[34] Fee DB, So YT, Barraza C, et al.. Phenotypic variability associated
with Arg26Gln mutation in caveolin3. Muscle Nerve 2004;30:375–8.
[35] Aboumousa A, Hoogendijk J, Charlton R, et al.. Caveolinopathy –
New mutations and additional symptoms. Neuromuscul Disord
2008;18(7):572–8.
[36] Olsen DB, Gideon P, Jeppesen TD, Vissing J. Leg muscle involve-
ment in facioscapulohumeral muscular dystrophy assessed by MRI. J
Neurol 2006;253(11):1437–41.
[37] Kan HE, Scheenen TW, Wohlgemuth M, et al.. Quantitative MR
imaging of individual muscle involvement in facioscapulohumeral
muscular dystrophy. Neuromuscul Disord 2009;19(5):357–62.
[38] Padberg GW. Facioscapulohumeral disease. In: Thesis, University of
Leiden, Leiden; 1982:133–134 (p. 23–24).
[39] Butz M, Koch MC, Mu¨ller-Felber W, Lemmers RJ, van der Maarel
SM, Schreiber H. Facioscapulohumeral muscular dystrophy. Pheno-
type-genotype correlation in patients with borderline D4Z4 repeat
numbers. J Neurol 2003;250(8):932–7.
[40] Tawil R, van der Maarel S, Padberg GW, van Engelen BG. 171st
ENMC international workshop: standards of care and management
of facioscapulohumeral muscular dystrophy. Neuromuscul Disord
2010;20(7):471–5.
[41] Padberg GW, Lunt PW, Koch M, Fardeau M. Diagnostic criteria for
facioscapulohumeral muscular dystrophy. Neuromuscul Disord
1991;1(4):231–4.
[42] Felice KJ, North WA, Moore SA, Matthews KD. FSH dystrophy
4q35 deletion in patients presenting with facial-sparing scapular
myopathy. Neurology 2000;54:1927–31.
[43] Felice KJ, Moore SA. Unusual clinical presentations in patients
harboring the facioscapulohumeral dystrophy 4q35 deletion. Muscle
Nerve 2000;24:352–6.
[44] van der Kooi AJ, Visser MC, Rosenberg N, et al.. Extension of the
clinical range of facioscapulohumeral dystrophy: report of six cases. J
Neurol Neurosurg Psychiatry 2000;69(1):114–6.
[45] Krasnianski M, Eger K, Neudecker S, Jakubiczka S, Zierz S. Atypical
phenotypes in patients with facioscapulohumeral muscular dystrophy
4q35 deletion. Arch Neurol 2003;60(10):1421–5.
[46] Zouvelou V, Manta P, Kalfakis N, Evdokimidis I, Vassilopoulos D.
Asymptomatic elevation of serum creatine kinase leading to the
diagnosis of 4q35 facioscapulohumeral muscular dystrophy. J Clin
Neurosci 2009;16(9):1218–9.
[47] Tsuji M, Kinoshita M, Imai Y, Kawamoto M, Kohara N.
Facioscapulohumeral muscular dystrophy presenting with hypertro-
phic cardiomyopathy: a case study. Neuromuscul Disord
2009;19(2):140–2.
[48] Reilich P, Schramm N, Schoser B, et al.. Facioscapulohumeral
muscular dystrophy presenting with unusual phenotypes and atypical
morphological features of vacuolar myopathy. J Neurol
2010;257(7):1108–18.
[49] Jordan B, Eger K, Koesling S, Zierz S. Camptocormia phenotype of
FSHD: a clinical and MRI study on six patients. J Neurol
2011;258(5):866–73.
[50] Kottlors M, Kress W, Meng G, Glocker FX. Facioscapulohumeral
muscular dystrophy presenting with isolated axial myopathy and bent
spine syndrome. Muscle Nerve 2010;42(2):273–5.
540 G. Ricci et al. / Neuromuscular Disorders 22 (2012) 534–540[51] Filosto M, Tonin P, Scarpelli M, et al.. Novel mitochondrial tRNA
Leu(CUN) transition and D4Z4 partial deletion in a patient with a
facioscapulohumeral phenotype. Neuromuscul Disord 2008;18(3):
204–9.
[52] Rudnik-Scho¨neborn S, Weis J, Kress W, Ha¨usler M, Zerres K.
Becker’s muscular dystrophy aggravating facioscapulohumeral mus-
cular dystrophy–double trouble as an explanation for an atypical
phenotype. Neuromuscul Disord 2008;18:881–5.
[53] Lecky BR, MacKenzie JM, Read AP, Wilcox DE. X-linked and FSH
dystrophies in one family. Neuromuscul Disord 1991;1:275–8.[54] Korngut L, Siu VM, Venance SL, et al.. Phenotype of combined
Duchenne and facioscapulohumeral muscular dystrophy. Neuromu-
scul Disord 2008;18(7):579–82.
[55] Chuenkongkaew WL, Suphavilai R, Vaeusorn L, Phasukkijwatana
N, Lertrit P, Suktitipat B. Proportion of 11778 mutant mitochondrial
DNA and clinical expression in a Thai population with Leber
hereditary optic neuropathy. J Neuroophthalmol 2005;25(3):173–5.
